UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Organ-on-a-chip models for development of cancer immunotherapies

Cancer Immunology, Immunotherapy, 2023-12, Vol.72 (12), p.3971-3983

2023

Volltextzugriff (PDF)

Serum-free production and purification of chimeric IgA antibodies

Journal of immunological methods, 2009-07, Vol.346 (1), p.26-37

2009

Volltextzugriff (PDF)

Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells"

The Journal of immunology (1950), 2018-04, Vol.200 (8), p.2517-2517

2018

Volltextzugriff (PDF)

The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells

Leukemia, 2013-01, Vol.27 (1), p.190-201

2013

Volltextzugriff (PDF)

Improvement of pharmacokinetics and myeloid effector cell engagement in vivo by Fc-engineering of IgA antibody against the epidermal growth factor receptor

European journal of cancer (1990), 2016-12, Vol.69, p.S144-S144

2016

Volltextzugriff (PDF)

Bispecific antibodies targeting cancer cells

Biochemical Society transactions, 2002-08, Vol.30 (4), p.507-511

2002

Volltextzugriff (PDF)

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity

Leukemia, 2012-04, Vol.26 (4), p.830-834

2012

Volltextzugriff (PDF)

9229 POSTER Severe Central Nervous System (CNS) Graft Versus Host Disease (GVHD) in a Patient Without Any Other GvHD Symptoms After Allogeneic Stem Cell Transplantation

European journal of cancer (1990), 2011, Vol.47, p.S647-S648

2011

Volltextzugriff (PDF)

Engineered CD3 antibodies for immunosuppression

Clinical and experimental immunology, 2003-09, Vol.133 (3), p.307-309

2003

Volltextzugriff (PDF)

Gsh‐1, an orphan Hox gene, is required for normal pituitary development

The EMBO journal, 1996-02, Vol.15 (4), p.714-724

1996

Volltextzugriff (PDF)

Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy

The Journal of immunology (1950), 2000-11, Vol.165 (10), p.5954-5961

2000

Volltextzugriff (PDF)

Human kappa light chain targeted Pseudomonas exotoxin A — identifying human antibodies and Fab fragments with favorable characteristics for antibody–drug conjugate development

Journal of immunological methods, 2011-08, Vol.371 (1-2), p.122-133

2011

Volltextzugriff (PDF)

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-Fc RI × anti-HER-2 neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

British journal of cancer, 2003-12, Vol.89 (12), p.2234-2243

2003

Volltextzugriff (PDF)

Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma

Blood, 2000-11, Vol.96 (10), p.3544-3552

2000

Volltextzugriff (PDF)

Recent genetic studies of mouse kidney development

Current opinion in genetics & development, 2004-10, Vol.14 (5), p.550-557

2004

Volltextzugriff (PDF)

Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia

Bone marrow transplantation (Basingstoke), 2022-07, Vol.57 (7), p.1116-1123

2022

Volltextzugriff (PDF)

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Bone marrow transplantation (Basingstoke), 2023-02, Vol.58 (2), p.222-225

2023

Volltextzugriff (PDF)

Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy

Critical reviews in oncology/hematology, 2001-04, Vol.38 (1), p.47-61

2001

Volltextzugriff (PDF)

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

Blood, 2004-09, Vol.104 (6), p.1793-1800

2004

Volltextzugriff (PDF)

Neutrophils Express the High Affinity Receptor for IgG (FcγRI, CD64) After In Vivo Application of Recombinant Human Granulocyte Colony-Stimulating Factor

Blood, 1991-08, Vol.78 (4), p.885-889

1991

Volltextzugriff (PDF)

Effector mechanisms of therapeutic antibodies against ErbB receptors

Current opinion in immunology, 2008-08, Vol.20 (4), p.436-443

2008

Volltextzugriff (PDF)

Dissecting a locus control region: facilitation of enhancer function by extended enhancer-flanking sequences

Molecular and Cellular Biology, 1995-02, Vol.15 (2), p.1123-1135

1995

Volltextzugriff (PDF)

440 - Improvement of pharmacokinetics and myeloid effector cell engagement in vivo by Fc-engineering of IgA antibody against the epidermal growth factor receptor

European journal of cancer (1990), 2016-12, Vol.69, p.S144-S144

2016

Volltextzugriff (PDF)

EPIDERMAL GROWTH FACTOR RECEPTOR AND G250: USEFUL TARGET ANTIGENS FOR ANTIBODY MEDIATED CELLULAR CYTOTOXICITY AGAINST RENAL CELL CARCINOMA?

The Journal of urology, 2002-02, Vol.167 (2), p.707-712

2002

Volltextzugriff (PDF)

Activated neutrophils as effector cells for bispecific antibodies

Cancer Immunology, Immunotherapy, 1997-11, Vol.45 (3-4), p.142-145

1997

Volltextzugriff (PDF)

1 – 25 von 1.649

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(856)
Mit Volltextzugriff
(961)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(507)
Life Sciences & Biomedicine
(433)
Roman Period, Ca. 500 Bc-600 Ad
(424)
Renaissance Period, 1500-1660
(337)
Commonwealth Interregnum Period, 1642-1660
(336)
Jacobean And Caroline Period, 1603-1660
(336)
Humans
(311)
Female
(151)
Animals
(128)
Biological And Medical Sciences
(128)
Male
(118)
Medical Sciences
(94)
Immunology
(93)
Adult
(80)
Mice
(69)
Proteins
(58)
Biochemistry & Molecular Biology
(57)
Hematology
(49)
Oncology
(47)
Immunotherapy
(45)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(546)
MEDLINE
(460)
Literature Online (LION)
(433)
Ingenta
(289)
Journals@Ovid Full Text
(256)
NUS Single-Journal Subscriptions
(232)
IngentaConnect Journals
(180)
Wiley-Blackwell Journals
(148)
Elsevier ScienceDirect Journals Collection
(123)
Ebook Central Perpetual and DDA
(115)
JSTOR
(113)
Wiley Online Library
(111)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(95)
Springer Journals
(60)
eBooks on EBSCOhost
(51)
Oxford Journals
(46)
De Gruyter eBooks
(43)
Taylor & Francis
(37)
Taylor & Francis Journals
(36)
Springer Nature - Connect here FIRST to enable access
(33)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(18)
... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Organ-on-a-chip models for development of cancer immunotherapies

Serum-free production and purification of chimeric IgA antibodies

Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells"

The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells

Improvement of pharmacokinetics and myeloid effector cell engagement in vivo by Fc-engineering of IgA antibody against the epidermal growth factor receptor

Bispecific antibodies targeting cancer cells

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity

9229 POSTER Severe Central Nervous System (CNS) Graft Versus Host Disease (GVHD) in a Patient Without Any Other GvHD Symptoms After Allogeneic Stem Cell Transplantation

Engineered CD3 antibodies for immunosuppression

Gsh‐1, an orphan Hox gene, is required for normal pituitary development

Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy

Human kappa light chain targeted Pseudomonas exotoxin A — identifying human antibodies and Fab fragments with favorable characteristics for antibody–drug conjugate development

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-Fc RI × anti-HER-2 neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma

Recent genetic studies of mouse kidney development

Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

Neutrophils Express the High Affinity Receptor for IgG (FcγRI, CD64) After In Vivo Application of Recombinant Human Granulocyte Colony-Stimulating Factor

Effector mechanisms of therapeutic antibodies against ErbB receptors

Dissecting a locus control region: facilitation of enhancer function by extended enhancer-flanking sequences

440 - Improvement of pharmacokinetics and myeloid effector cell engagement in vivo by Fc-engineering of IgA antibody against the epidermal growth factor receptor

EPIDERMAL GROWTH FACTOR RECEPTOR AND G250: USEFUL TARGET ANTIGENS FOR ANTIBODY MEDIATED CELLULAR CYTOTOXICITY AGAINST RENAL CELL CARCINOMA?

Activated neutrophils as effector cells for bispecific antibodies

Suchergebnisse filtern